The estimated Net Worth of Cameron John Reynolds is at least $1.71 Million dollars as of 8 December 2023. Mr. Reynolds owns over 10,000 units of VolitionRX Ltd stock worth over $1,191,458 and over the last 10 years he sold VNRX stock worth over $0. In addition, he makes $517,691 as President, Chief Executive Officer, and Director at VolitionRX Ltd.
Cameron has made over 12 trades of the VolitionRX Ltd stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of VNRX stock worth $6,700 on 8 December 2023.
The largest trade he's ever made was selling 1,038,000 units of VolitionRX Ltd stock on 3 September 2014 worth over $725,562. On average, Cameron trades about 33,840 units every 94 days since 2014. As of 8 December 2023 he still owns at least 1,704,518 units of VolitionRX Ltd stock.
You can see the complete history of Mr. Reynolds stock trades at the bottom of the page.
Cameron John Reynolds serves as President, Chief Executive Officer, Director of the Company. Prior to completion of the transactions under the Share Exchange Agreement, he was Chief Executive Officer and Director of Singapore Volition, a position he held since August 5, 2010. He is also a Manager of Belgian Volition since October 27, 2010, serving as Managing Director between January 18, 2012 and July 24, 2015, a Director and Chief Executive Officer of Volition Diagnostics since November 13, 2015, a Director of Volition America since February 3, 2017 and was appointed a Manager of Volition Vet, on August 7, 2019. Since February 2017, Mr. Reynolds has also served as a non-executive director of Ucroo Incorporated, a developer of a secure web and mobile platform that integrates with existing college systems to provide a thriving digital campus where students are better connected, supported and engaged, and, since July 2018, as a non-executive director of OBJ Limited (ASX: OBJ), a developer of magnetic, micro-array drug and ingredient delivery technologies for use in pharmaceutical, cosmetic and skincare, and consumer healthcare industries. From 2004 until 2011, Mr. Reynolds founded and served as Managing Director and Director of Mining House Ltd, where he was responsible for identifying potential mining projects, coordinating the preliminary evaluations and securing the financing with a view to listing the companies on the AIM, the TSX and the U.S. OTC. Mr. Reynolds furthered his education between 2002 and 2003 as he undertook an MBA. From 1998 until 2001, Mr. Reynolds served as the commercialization director for Probio, Inc., a company that commercialized intellectual property in the animal biotechnology fields including transgenesis and cloning research from the University of Hawaii. Mr. Reynolds’ main responsibilities were managing all legal and contract issues with the University of Hawaii, implementing patenting strategy, managing all stockholder issues including the merger and its legal and contractual doc
As the President, Chief Executive Officer, and Director of VolitionRX Ltd, the total compensation of Cameron Reynolds at VolitionRX Ltd is $517,691. There are no executives at VolitionRX Ltd getting paid more.
Cameron Reynolds is 48, he's been the President, Chief Executive Officer, and Director of VolitionRX Ltd since 2011. There are 14 older and 4 younger executives at VolitionRX Ltd. The oldest executive at VolitionRX Ltd is Dr. Martin Charles Faulkes Ph.D., 77, who is the Exec. Chairman.
Cameron's mailing address filed with the SEC is 1489 WEST WARM SPRINGS ROAD, SUITE 110, HENDERSON, NV, 89014.
Over the last 12 years, insiders at VolitionRX Ltd have traded over $775,239 worth of VolitionRX Ltd stock and bought 1,908,474 units worth $44,487,770,972 . The most active insiders traders include Guy Archibald Innes, Cameron John Reynolds, and Martin Charles Faulkes. On average, VolitionRX Ltd executives and independent directors trade stock every 43 days with the average trade being worth of $27,899. The most recent stock trade was executed by Guy Archibald Innes on 20 August 2024, trading 150,000 units of VNRX stock currently worth $100,500.
volitionrx is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats. volitionrx’s development activities are currently centered in belgium with a focus on bringing its revolutionary diagnostic products to market first in europe, then the u.s. and worldwide. you can find more information about volitionrx at our website at www.volitionrx.com, on twitter at www.twitter.com/volitionrx, linkedin at http://www.linkedin.com/company/volitionrx or facebook at www.facebook.com/volitionrx.
VolitionRX Ltd executives and other stock owners filed with the SEC include: